NANOBIOTIX
Live / Registered — Registered (as of 10 Aug 2021)
What this means for you
Registered since 10 Aug 2021. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (the §71 affidavit of use is due by 10 Aug 2027, and its filing window is open now).
Record
- Serial number
- 79293376
- Registration number
- 6443537
- Mark type
- Stylized text
- Filed
- 17 Jul 2020
- Published for opposition
- 25 May 2021
- Registered
- 10 Aug 2021
- Next maintenance filing
- §71 affidavit of use, due by 10 Aug 2027 (grace period to 10 Feb 2028)
- Attorney of record
- James R Menker
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products, namely, preparations for medical use particularly for tumor diagnosis and treatment; pharmaceutical products, namely, preparations for medical use, especially for the diagnosis and treatment of tumors using radiotherapy; radioactive products, namely, substances for medical use, especially for the diagnosis and treatment of tumors using radiotherapy; health products, namely, pharmaceutical products, for the treatment of tumors; radiological contrast substances for medical use; chemical reagents for medical use; chemical preparations for medical or pharmaceutical use, namely, for the treatment of tumors; diagnostic products for medical use, namely, medicines for the treatment of tumors; drugs for medical use, namely, pharmaceutical products for use in the treatment of cancer; medicines for human medicine, namely, pharmaceutical products for the treatment of tumors; chemico-pharmaceutical products for use in treating oncological diseases and disorders; pharmaceutical products for use in treating oncological diseases and disorders
- Class 010 — Medical apparatus: Surgical and medical apparatus and instruments, namely radiotherapy apparatus especially for the diagnosis and treatment of tumors using radiotherapy; radiotherapy apparatus; testing apparatus for medical use, namely, for testing tumor characteristics; diagnostic apparatus for medical use, namely, for testing tumor characteristics; radiological apparatus for medical use; apparatus and installations for the production of X-Rays for medical use
- Class 042 — Scientific and technological services: Scientific and technological services, namely, research and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; scientific research, namely, evaluations, estimates and research in scientific and technological fields provided by engineers, researchers; design and development of new products for third parties; technical project studies, namely, technical research in the field of nanomedicine; industrial analysis of manufacturing of nanomedicines and research services in the field of nanomedicine; chemical analysis; chemical research; chemistry services, namely, chemistry consultation; surveying
- Class 044 — Medical, beauty and agricultural services: Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
Owner
- NANOBIOTIX, FR
- NANOBIOTIX, FR
- NANOBIOTIX, FR
Prosecution history
- 10 Aug 2026 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 19 Dec 2021 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 01 Dec 2021 — FINAL DISPOSITION NOTICE SENT TO IB
- 01 Dec 2021 — FINAL DISPOSITION PROCESSED
- 10 Nov 2021 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 10 Aug 2021 — REGISTERED-PRINCIPAL REGISTER
- 25 May 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 May 2021 — PUBLISHED FOR OPPOSITION
- 23 May 2021 — NOTIFICATION PROCESSED BY IB
- 05 May 2021 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 05 May 2021 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 05 May 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Apr 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Apr 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Apr 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE